

## **Exosome Dx enters partnership with Takeda**

**Cambridge, Mass., June. 30, 2016** – Exosome Diagnostics, Inc., the world’s only provider of an exosome liquid biopsy platform to monitor disease biomarkers in patient blood, with the goal of reducing or eliminating the need for tissue biopsies, has entered into a collaboration with Takeda Pharmaceuticals International Co. to develop an exosomal RNA sequencing platform for biomarkers.

As part of the agreement, Exosome Diagnostics will establish a gene expression pipeline with Takeda that will utilize its exosomal RNA isolation technology, RNA-Seq biomarker discovery platform, proprietary algorithms, signal enhancement technology, and additional ancillary technologies for analysis of exosomal RNA. The goal of the pipeline is to develop a platform for serial analysis of gene expression patterns in patients with cancer, as well as additional disease states beyond oncology.

“Analysis of RNAs in exosomes may provide an innovative biomarker tool for longitudinal patient characterization to select patients, monitor disease and track drug response over time of therapy without the need for multiple tissue biopsies. Such monitoring may enable appropriate patient selection to direct the most effective therapy to patients with cancer as well as other indications, such as CNS disorders.” stated Andy Dorner, VP of Translational & Biomarker Research for Takeda. “Specialized omics applications are rapidly changing the landscape of translational medicine; this makes it essential for Takeda to form partnerships with innovative companies, such as Exosome Diagnostics, to further our goal of improving patients’ lives,” Dorner continued.

“We are excited to begin our partnership with Takeda,” stated Mario Morken, Head of Business Development for Exosome Diagnostics. “Exosome Diagnostics’ technology can enable discovery and development of novel biomarkers that can allow physicians to give the right drug to the right patient at the right time. This partnership highlights Exosome Diagnostics’ capabilities to drive the commercial success of targeted therapies.”

“Exosome is very pleased to be chosen by Takeda for our expertise in exosome isolation and analysis. This collaboration aims to develop a biomarker discovery platform that will further Takeda’s efforts to provide therapeutics that may significantly improve the quality of the patients’ lives,” stated John Boyce, President and CEO of Exosome Diagnostics. “We have made great progress in maturing our biomarker discovery, companion diagnostics development, and commercialization organization over the past year. Takeda is a very well respected and forward-looking company that Exosome Diagnostics is honored to be partnered with,” Boyce continued.

### **About Exosome Diagnostics**

Exosome Diagnostics is a privately held company focused on developing and commercializing revolutionary biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. Exosome Diagnostics is leveraging its proprietary platform to establish a world class companion diagnostics program to enable pharmaceutical companies to rapidly stratify patient enrollment for clinical trials as well to monitor therapeutic response from plasma, urine, and saliva. The company's novel exosome-based technology platform, ExoLution™, can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated and monitored. Visit [www.exosomedx.com](http://www.exosomedx.com) to learn more.

ExoDx is a registered trademark of Exosome Diagnostics, Inc. Exosome Diagnostics and ExoLution are unregistered trademarks of Exosome Diagnostics, Inc.

**Company Contact:**

Dan Baughman

Exosome Diagnostics

[dbaughman@exosomedx.com](mailto:dbaughman@exosomedx.com)

248-613-2247